リンパ腫のやさしい講義

出版社： メジカルビュー社
著者：
発行日： 2015-07-20
分野： 臨床医学：内科  >  血液
ISBN： 9784758303903
電子書籍版： 2015-07-20 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

4,620 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,620 円(税込)

購入する

商品紹介

「リンパ腫は難しい」「どこから学んでよいかわからない」と多岐にわたる病型分類やめまぐるしい治療の進歩にお悩みの方に送る、「気軽に読めるのに、すぐよくわかる！」これまでになかった待望の一冊。講義形式のやさしい語り口で、ガイドラインや成書の行間から最新治療までをかみ砕いて解説。若手医師の悩みをよく知る著者だからこそできる、ここがわからなかった・そこが知りたかったに丁寧に答える。リンパ腫について学び始める方・学びたい方、必読の入門書。

目次

  • リンパ腫のやさしい講義

    ―目次―

    1 悪性リンパ腫を正確に診断するために
    2 リンパ節が腫れる疾患を鑑別するために
    3 リンパ腫を治療する前に知っておきたいこと
    4 知っておくと便利；リンパ腫の予後因子について学びましょう
    5 リンパ腫といえば；ホジキンリンパ腫
    6 臨床医が知っておきたいホジキンリンパ腫の診断
    7 古典的ホジキンリンパ腫の治療方針を決定するために
    8 限局期古典的ホジキンリンパ腫の治療方針
    9 進行期古典的ホジキンリンパ腫の治療方針
    10 再発または難治性古典的ホジキンリンパ腫の治療方針；
    期待の新薬も登場
    11 非ホジキンリンパ腫は、なぜ多くの病型に分けることが必要か
    12 非ホジキンリンパ腫を治療するために知っておきたいポイント；
    　　 薬物有害事象とその対策を中心に
    13 びまん性大細胞型B細胞リンパ腫の治療を開始する前に
    　　 知っておきたいこと
    14 限局期びまん性大細胞型B細胞リンパ腫の治療方針
    15 進行期びまん性大細胞型B細胞リンパ腫の治療方針
    16 再発または難治性びまん性大細胞型B 細胞リンパ腫の治療方針
    17 最近話題の中間型リンパ腫
    18 血液内科医以外が診断することの多い
    節外性リンパ腫の基本知識
    19 知っておきたい消化管B細胞リンパ腫について
    20 代表的な節外性びまん性大細胞型B細胞リンパ腫
    21 不明熱の鑑別で重要な血管内大細胞型B細胞リンパ腫
    22 知っておきたい濾胞性リンパ腫の基礎知識
    23 濾胞性リンパ腫の治療方針
    24 R-CHOP 療法では予後不良なマントル細胞リンパ腫
    25 再発あるいは治療抵抗性低悪性度リンパ腫の治療
    26 急速に進行するバーキットリンパ腫
    27 T細胞リンパ腫を代表する末梢性T細胞リンパ腫,非特異群
    28 T 細胞リンパ腫のなかでは予後が良好な
    未分化大細胞型リンパ腫
    29 臨床的にも病理学的にも鑑別の難しい
    血管免疫芽球性T細胞リンパ腫
    30 日本人に多い成人T 細胞白血病・リンパ腫
    31 特殊な病型でアジアに多い節外性NK/T 細胞リンパ腫，鼻型

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1 悪性リンパ腫を正確に診断するために

P.15 掲載の参考文献
1) The world health organization classification of malignant lymphomas in japan:incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists. Pathol Int 2000;50:696-702.
 
2) 岡本昌隆. 6. 悪性リンパ腫の病型頻度. 吉野 正, 中峯寛和, 岡本昌隆, 新津 望, 編著. 悪性リンパ腫臨床と病理-WHO分類(第4版)に基づいて. 東京:先端医学社;2009. p74-81.
 
3) 一般社団法人 日本血液学会, 編. 造血器腫瘍診療ガイドライン2013年版. 東京:金原出版;2013. p135.
 

2 リンパ節が腫れる疾患を鑑別するために

P.21 掲載の参考文献
1) 新津 望. リンパ節腫脹をきたす疾患. 悪性リンパ腫診療スキルアップ. 東京:中外医学社;2012. p2-6.
 

3 リンパ腫を治療する前に知っておきたいこと

P.26 掲載の参考文献
1) 第3部 悪性リンパ腫 4病期分類. 日本血液学会, 日本リンパ網内系学会, 編. 造血器腫瘍取扱い規約(第1版). 東京:金原出版;2010. p121-7.
 

4 知っておくと便利 ; リンパ腫の予後因子について学びましょう

P.33 掲載の参考文献
1) The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-94.
 
2) Hasenclever D, et al. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506-14.
PubMed
3) Nogova L, et al. Lymphocyte-predominant and classical Hodgkin's lymphoma:a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2008;26:434-9.
 
4) Zhou Z, et al. An enhanced International Prognostic Index(NCCN-IPI)for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 2014;123:37-42.
 

6 臨床医が知っておきたいホジキンリンパ腫の診断

P.40 掲載の参考文献
1) Swerdlow SH, et al, eds. WHO classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th Ed. Lyon:IARC Press;2008.
 
2) 田丸淳一. 各論A セミナー12 Hodgkinリンパ腫. 日本リンパ網内系学会(編集責任者;新津 望, 山口素子), 編. 若手医師のためのリンパ腫セミナー. 東京:南江堂;2012. p72-5.
 

7 古典的ホジキンリンパ腫の治療方針を決定するために

P.43 掲載の参考文献
1) Engert A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma:results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003;21:36018.
 
2) Henry-Amar M, et al. Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC Lymphoma Cooperative Group. Ann Intern Med 1991;114:361-5.
PubMed
3) Meyer RM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limitedstage Hodgkin's lymphoma:National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:4634-42.
 

8 限局期古典的ホジキンリンパ腫の治療方針

P.51 掲載の参考文献
1) Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-84.
PubMed
2) Bonadonna G, Bonfante V, Viviani S, et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease:long-term results. J Clin Oncol 2004;22:2835-41.
PubMed
3) Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010;363:640-52.
 
4) Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma:results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003;21:3601-8.
 
5) Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma:final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010;28:4199-206.
 

9 進行期古典的ホジキンリンパ腫の治療方針

P.56 掲載の参考文献
1) Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-84.
PubMed
2) Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386-95.
PubMed
3) Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma:10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009;27:4548-54.
 
4) Meignan M, Gallamini A, Haioun C, et al. Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010. Leuk Lymphoma 2010;51:2171-80.
PubMed

10 再発または難治性古典的ホジキンリンパ腫の治療方針 ; 期待の新薬も登場

P.64 掲載の参考文献
1) Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease:results of a BNLI randomised trial. Lancet 1993;341:1051-4.
PubMed
2) Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease:a randomised trial. Lancet 2002;359:2065-71.
PubMed
3) Moskowitz CH, Yahalom J, Zelenetz AD, et al. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol 2010;148:890-7.
PubMed
4) Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 2002;20:221-30.
 
5) Younes A, Gopal AK, Smith SE, et al. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma. J Clin Oncol 2012;30:2183-9.
 
6) Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015;372:311-9.
 

11 非ホジキンリンパ腫は、なぜ多くの病型に分けることが必要か

P.69 掲載の参考文献
1) 日本血液学会, 編. 造血器腫瘍診療ガイドライン2013年版. 東京:金原出版:2013.
 
2) Hvizdala EV, Berard C, Callihan T, et al. Nonlymphoblastic lymphoma in children--histology and stage-related response to therapy:a Pediatric Oncology Group study. J Clin Oncol 1991;9:1189-95.
 
3) Aviles A, Nambo MJ, Neri N, et al. The role of surgery in primary gastric lymphoma:results of a controlled clinical trial. Ann Surg 2004;240:44-50.
PubMed

13 びまん性大細胞型B細胞リンパ腫の治療を開始する前に知っておきたいこと

P.80 掲載の参考文献
1) Hans CP, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-82.
PubMed
2) Yamaguchi M, et al. De novo CD5+ diffuse large B-cell lymphoma:a clinicopathologic study of 109 patients. Blood 2002;99:815-21.
PubMed
3) Miyazaki K, et al. CD5-positive diffuse large B-cell lymphoma:a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol 2011;22:1601-7.
PubMed

14 限局期びまん性大細胞型B細胞リンパ腫の治療方針

P.86 掲載の参考文献
1) 第3部 悪性リンパ腫 4. 病期分類. 日本血液学会, 日本リンパ網内系学会編集, 編. 造血器腫瘍取扱い規約 第1版. 東京:金原出版;2010. p121-7.
 
2) Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998;339:21-6.
PubMed
3) Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma:Southwest Oncology Group study 0014. J Clin Oncol 2008;26:2258-63.
 

15 進行期びまん性大細胞型B細胞リンパ腫の治療方針

P.93 掲載の参考文献
1) Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen(CHOP)with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-6.
PubMed
2) Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
PubMed
3) Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with goodprognosis diffuse large-B-cell lymphoma:a randomised controlled trial by the MabThera International Trial(MInT)Group. Lancet Oncol 2006;7:379-91.
PubMed

16 再発または難治性びまん性大細胞型B細胞リンパ腫の治療方針

P.98 掲載の参考文献
1) Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-5.
PubMed
2) Vellenga E, van Putten WL, van't Veer MB, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL:a prospective randomized HOVON trial. Blood 2008;111:537-43.
PubMed
3) Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:4184-90.
 

17 最近話題の中間型リンパ腫

P.102 掲載の参考文献
1) Niitsu N, Okamoto M, Miura I, et al. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18)and 8q24/c-MYC translocations. Leukemia 2009;23:777-83.
 

18 血液内科医以外が診断することの多い節外性リンパ腫の基本知識

P.107 掲載の参考文献
1) Nakamura S, Matsumoto T, Ye H, et al. Helicobacter pylori-negative gastric mucosaassociated lymphoid tissue lymphoma:a clinicopathologic and molecular study with reference to antibiotic treatment. Cancer 2006;107:2770-8.
PubMed

19 知っておきたい消化管B細胞リンパ腫について

P.113 掲載の参考文献
1) Aviles A, Nambo MJ, Neri N, et al. The role of surgery in primary gastric lymphoma:results of a controlled clinical trial. Ann Surg 2004;240:44-50.
PubMed
2) Tanaka T, Shimada K, Yamamoto K, et al. Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era:a multicenter study of 95 patients in Japan. Ann Hematol 2012;91:383-90.
 
3) Yoshino T, Miyake K, Ichimura K, et al. Increased incidence of follicular lymphoma in the duodenum.Am J Surg Pathol 2000;24:688-93.
PubMed

20 代表的な節外性びまん性大細胞型B細胞リンパ腫

P.119 掲載の参考文献
1) Ferreri AJ. How I treat primary CNS lymphoma. Blood 2011;118:510-22.
 
2) Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma:a randomised phase 2 trial. Lancet 2009;374:1512-20.
PubMed

21 不明熱の鑑別で重要な血管内大細胞型B細胞リンパ腫

P.124 掲載の参考文献
1) Murase T, Yamaguchi M, Suzuki R, et al. Intravascular large B-cell lymphoma(IVLBCL):a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood 2007;109:478-85.
 
2) Shimada K, Matsue K, Yamamoto K, et al. Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. J Clin Oncol 2008;26:3189-95.
 

22 知っておきたい濾胞性リンパ腫の基礎知識

P.130 掲載の参考文献
1) Freedman A. Follicular lymphoma:2014 update on diagnosis and management. Am J Hematol 2014;89:429-36.
PubMed
2) Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa:a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997;15:1110-7.
PubMed

23 濾胞性リンパ腫の治療方針

P.137 掲載の参考文献
1) Pendlebury S, el Awadi M, Ashley S, et al. Radiotherapy results in early stage low grade nodal non-Hodgkin's lymphoma. Radiother Oncol 1995;36:167-71.
PubMed
2) Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin's lymphoma:long-term follow-up of no initial therapy. J Clin Oncol 2004;22:1454-9.
 
3) Ardeshna KM, Qian W, Smith P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma:an open-label randomised phase 3 trial. Lancet Oncol 2014;15:424-35.
PubMed
4) Federico M, Luminari S, Dondi A R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma:results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol 2013;31:1506-13.
PubMed
5) Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy(PRIM):a phase 3, randomised controlled trial. Lancet 2011;377:42-51.
 

24 R - CHOP療法では予後不良なマントル細胞リンパ腫

P.143 掲載の参考文献
1) Hoster E, Dreyling M, Klapper W, et al German Low Grade Lymphoma Study Group(GLSG);European Mantle Cell Lymphoma Network. A new prognostic index(MIPI)for patient s with advanced-stage mantle cell lymphoma. Blood 2008;111:558-65.
 
2) Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:7013-23.
PubMed
3) Mujtaba T, Dou QP. Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med 2011;12:471-80.
PubMed

25 再発あるいは治療抵抗性低悪性度リンパ腫の治療

P.148 掲載の参考文献
1) Zelenetz AD. Radioimmunotherapy for lymphoma. Curr Opin Oncol 1999;11:375-80.
PubMed
2) Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:5156-64.
PubMed
3) Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas:an open-label, multicentre, randomised, phase 3 noninferiority trial. Lancet 2013;381:1203-10.
PubMed
4) Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustinerituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL:the BRIGHT study. Blood 2014;123:2944-52.
 
5) Salles GA, Morschhauser F, Solal-Celigny P, et al. Obinutuzumab(GA101)in patients with relapsed/refractory indolent non-Hodgkin lymphoma:results from the phase II GAUGUIN study. J Clin Oncol 2013;31:2920-6.
PubMed
6) Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014;370:1008-18.
 

26 急速に進行するバーキットリンパ腫

P.152 掲載の参考文献
1) Mead GM, Barrans SL, Qian W, et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria(MRC/NCRI LY10 trial). Blood 2008;112:2248-60
PubMed
2) Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006;106:1569-80.
PubMed

27 T細胞リンパ腫を代表する末梢性T細胞リンパ腫, 非特異群

P.158 掲載の参考文献
1) Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified(PTCL-U):a new prognostic model from a retrospective multicentric clinical study. Blood 2004;103:2474-9.
 
2) Vose J, Armitage J, Weisenburger D. International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study:pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124-30.
PubMed
3) Schmitz N, Trumper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma:an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010;116:3418-25.
 

28 T細胞リンパ腫のなかでは予後が良好な未分化大細胞型リンパ腫

P.164 掲載の参考文献
1) Falini B, Pileri S, Zinzani PL, et al. ALK+ lymphoma:clinico-pathological findings and outcome. Blood 1999;93:2697-706.
PubMed
2) Sibon D, Fournier M, Briere J, et al. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials. J Clin Oncol 2012;30:3939-46.
 
3) Fanale MA, Horwitz SM, Forero-Torres A, et al. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas:results of a phase I study. J Clin Oncol 2014;32:3137-43.
PubMed
4) Gambacorti Passerini C, Farina F, Stasia A, et al. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. J Natl Cancer Inst 2014;106:djt378.
PubMed

29 臨床的にも病理学的にも鑑別の難しい血管免疫芽球性T細胞リンパ腫

P.169 掲載の参考文献
1) Mourad N, Mounier N, Briere J, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte(GELA)trials. Blood 2008;111:4463-70.
 
2) Tokunaga T, Shimada K, Yamamoto K, et al. Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma:a multicenter cooperative study in Japan. Blood 2012;119:2837-43.
PubMed

30 日本人に多い成人T細胞白血病・リンパ腫

P.175 掲載の参考文献
1) 日本血液学会, 編. 造血器腫瘍診療ガイドライン2013年版. 東京:金原出版;2013.
 
2) Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma:Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 2007;25:5458-64.
 
3) Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody(KW-0761)for relapsed adult T-cell leukemia-lymphoma:a multicenter phase II study. J Clin Oncol 2012;30:837-42.
PubMed
4) Ishida T, Inagaki H, Utsunomiya A, et al. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res 2004;10:5494-500.
 

31 特殊な病型でアジアに多い節外性NK / T細胞リンパ腫, 鼻型

P.180 掲載の参考文献
1) Kwong YL. The diagnosis and management of extranodal NK/T-cell lymphoma, nasal-type and aggressive NK-cell leukemia. J Clin Exp Hematop 2011;51:21-8.
PubMed
2) Yamaguchi M, Tobinai K, Oguchi M, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma:Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 2009;27:5594-600.
 
3) Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer(NK)/T-cell lymphoma, nasal type:the NK-Cell Tumor Study Group study. J Clin Oncol 2011;29:4410-6.
PubMed

書評

最近チェックした商品履歴

Loading...